AstraZeneca has announced positive high-level results from its Phase III KALOS and LOGOS trials, showing significant promise ...

AstraZeneca (AZN) said on Friday that it received positive results from two late-stage trials for its triple-combination ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Breztri Aerosphere, a triple inhaled therapy, met its primary endpoint of lung function improvement in adults and adolescents ...

The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.

AstraZeneca's Breztri met primary goals in four asthma trials, including KALOS, LOGOS, LITHOS, and VATHOS, involving over ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

May 2 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday its triple-combination inhaler Breztri Aerosphere met all main goals in two late-stage trials for uncontrolled asthma ...

AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat ...

AstraZeneca PLC on Friday announced that its triple-combination asthma inhaler Breztri met all primary endpoints in t ... Subscribe now to see this Premium News article from Alliance News ...

AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...

AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of Breztri ...